Case Report: A Patient With COVID-19 Who Benefited From Hemoadsorption

Yinke Du; Zhipeng Qi; Jiangwei Ma; Da Sun; Li Yao; Bin Xu; Wei Liu; Zhaofa Xu; Yu Deng

doi:10.3389/fmed.2020.607849

Case Report: A Patient With COVID-19 Who Benefited From Hemoadsorption

Front Med (Lausanne). 2020 Dec 1:7:607849. doi: 10.3389/fmed.2020.607849. eCollection 2020.

Authors

Yinke Du¹, Zhipeng Qi², Jiangwei Ma³, Da Sun¹, Li Yao¹, Bin Xu², Wei Liu², Zhaofa Xu², Yu Deng²

Affiliations

¹ Department of Nephrology, First Hospital of China Medical University, Shenyang, China.
² Department of Environmental Health, School of Public Health, China Medical University, Shenyang, China.
³ Department of Pulmonary and Critical Care Medicine, First Hospital of China Medical University, Shenyang, China.

Abstract

In December 2019, the 2019 novel coronavirus disease (COVID-19), which has been identified to be caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China and spread across the world. Higher plasma levels of cytokines, including interleukin (IL)-6, IL-2, IL-7, IL-10, and tumor necrosis factor-α, were found in patients with COVID-19, which implies the occurrence of a cytokine storm and its association with disease severity. Extracorporeal blood purification has been proven to effectively remove the released inflammatory cytokines. In this study, we report on a patient with COVID-19 who benefited from hemoadsorption.

Keywords: 2019-nCoV; COVID-19; epidemic; extracorporeal blood purification; treatment.

Publication types

Case Reports